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Differentiation of ABO mosaics from chimeras is performed using 
flow cytometry (FCM) analysis. Although mosaics and chimeras 
have been distinguished by presence or absence of clear resolution 
using FCM analysis, the lack of quantitative metrics and definitive 
criteria for this differentiation has made some cases difficult to 
differentiate. In this study, therefore, we attempted to establish a 
definitive and quantitative criterion for this differentiation. When 
FCM histogram gates for group “A” or “B” antigen-negative and 
-positive red blood cells (RBCs) were set such that group O RBCs 
were classified as 99 percent negative and group A or B RBCs as 99 
percent positive, the percentages of RBCs in the middle region of 
six chimeras and 23 mosaics (12 A mosaics and 11 B mosaics) were 
0.1–0.6 percent and 7.0–19.0 percent, respectively. This result 
suggested that ABO mosaics and chimeras can be unambiguously 
differentiated when the cutoff point of the intermediate region is 
set to 1 percent. Immunohematology 2015;31:24–28.
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The differentiation of ABO subgroups is usually 
determined serologically on the basis of the following: (1) 
agglutination tests with human polyclonal anti-A, anti-B, and 
anti-A1 lectin; (2) identification of anti-A or anti-B in serum; 
and (3) ABO transferase activity. ABO mosaics and chimeras 
are usually differentiated from other subgroups using these 
tests.1–5 Consequently, mosaics and chimeras are differentiated 
by coil planet centrifugation (CPC)6 or flow cytometry (FCM) 
methods.7–9 Genotyping is useful as a supplementary tool to 
confirm the final differentiation of these ABO subgroups.1,2 
Although ABO mosaics and chimera can be easily differentiated 
from other subgroups, it is difficult to differentiate them from 
each other using standard serologic methods,3,4 and only 
CPC and FCM methods are available for this purpose. The 
coil planet centrifuge is no longer manufactured and is thus 
difficult to obtain. Furthermore, distinguishing ABO mosaics 
from chimeras using the FCM method is based simply on the 
presence or absence of clear resolution of positive and negative 
peaks. This lack of quantitative metrics has made some 
cases difficult to differentiate because there are no definitive 
criteria for this determination. In addition, a quantitative FCM 
method appears promising for diagnosing early relapse or 
rejection after hematopoietic progenitor cell transplantation 
using ABO-incompatible cells.10 Therefore, in the present 
study, we developed a quantitative criterion for FCM-based 
differentiation of ABO mosaics from chimeras by setting 
a gate between the “A” or “B” antigen-negative and -positive 
red blood cell (RBC) populations in the FCM histogram and 
then determining the proportion of cells in the middle gate. 
Quantitative tests such as this FCM system should be applied 
to other qualitative serologic tests.
Materials and Methods
Blood Samples
Twelve A mosaic samples, 11 B mosaic samples, and 6 
ABO chimera samples were obtained from volunteer blood 
donors in the Kinki area of Japan. These samples were 
previously identified as mosaics or chimeras based on the 
following: (1) agglutination tests with monoclonal anti-A, 
anti-B, anti-A1 lectin, and anti-H lectin; (2) identification of 
anti-A or anti-B in serum; and (3) ABO transferase activity 
in plasma. Consequently, the possibility of other subgroups 
including A1, A2, A3, and Ax were ruled out.1,2 Similarly, B, B3, 
and Bx were ruled out. In addition, their phenotypes as mosaics 
or chimeras were confirmed by the CPC method, which can 
detect ABO chimerism as low as 0.1 percent.6 A flow chart 
outlining the classification of ABO mosaics, chimeras, and 
other subgroups is presented in Figure 1. We did not perform 
a family study to determine if any of the donors were related. 
It is likely that most of the donors were unrelated, however, 
because they all had different family names and lived in widely 
scattered regions.
ABO Genotyping
Genomic DNA was prepared from 200 μL ethylene-
diaminetetraacetic acid (EDTA) whole blood using a collection 
system (Quick whole blood kit, KURABO Industries, Osaka, 
Japan). The polymerase chain reaction–reverse sequence 
specific oligonucleotide (PCR-rSSO) method was performed 
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to detect single nucleotide polymorphisms (SNPs) on ABO 
alleles. Amplicons labeled with fluorescence were separately 
amplified by PCR from ABO exons 6 and 7 using an automated 
system (GeneAmp PCR System 9700, Applied Biosystems, 
Foster City, CA,) and the group-specific reagent (Genosearch 
ABO reagent, Medical & Biological Laboratories, Nagano, 
Japan). We detected SNPs on ABO alleles using a florescent 
system (Luminex System 200, Hitachi Solutions, Tokyo, 
Japan). In addition, we confirmed the DNA sequence of exon 7 
on both A and B alleles by direct PCR sequencing. We 
first amplified exon 7 on both alleles using the primers 
GA22 and GA23 (Table 1). Each PCR contained 2.5 
μL genomic DNA, 1 μL GA22, 1 μL GA23, 35.25 μL 
sterile water (distilled deionized sterile water, Nippon 
Gene Co. Ltd., Toyama, Japan), 5 μL of a dNTP mix at 
a concentration of 2 mmol/L of each dNTP (GeneAmp 
Applied Biosystems), 5 μL of a 10× buffer (PCR buffer, 
Applied Biosystems), and 0.25 μL of a Taq amplifier in 
a concentration of 250 U at 5 U/μL (AmpliTaq Gold, Applied 
Biosystems). PCR amplification was performed with initial 
denaturation at 96°C for 2 minutes, followed by 35 cycles at 
96°C for 1 minute, 62°C for 1 minute, and 72°C for 4 minutes. 
For DNA sequencing analysis, the PCR fragments, which 
were purified, (QIAquick PCR purification kit,QIAGEN, 
Hilden, Germany), were fluorescently labeled with primer 
GA62 or GA03 (Table 1) using a cycle sequencing kit (BigDye 
Terminator v1.1, Applied Biosystems). The DNA sequences 
Fig. 1. Flow chart outlining the classification of ABO mosaics, chimeras, and other subgroups. Broken arrows and broken squares indicate 
supplementary tools used to confirm the final differentiation of these ABO subgroups.
Table 1. Primers used for amplification and direct sequencing of ABO 
gene fragments
Primer 





GA22 CTAAAACCAAGGGCGGGAGG reverse 3′-UTR
GA23 GAAGGATGTCCTCGTGGTGA forward exon 6 exon 6–7
GA62 TCAGGACAGGGCAGGAGAACG forward intron 6 exon7
GA03 TGCTGGAGGTGCGCGCCTAC forward exon 7 exon 7
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were measured using a genetic analyzer (ABI PRISM 3130×L, 
Applied Biosystems). The loci c.261 and c.297 in exon 6 and 
c.467, c.526, c.547, c.646, c.657, c.681, c.703, c.771, c.771, 
c.784, c.796, c.802, c.803, c.829, c.871, c.930, c.1006, c.1054, 
and c.1060 in exon 7 were analyzed, and the results indicated 
that all of the samples that we could analyze were either A102 
or B101 (Table 2).
Preparation of Cell Samples for FCM Analysis
A 10-µL RBC suspension (whole blood collected in 
K2EDTA) was washed three times in phosphate-buffered 
saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA) and fixed by 
mixing with 50 μL of 0.25% glutaraldehyde (Nacalai Tesque, 
Inc., Kyoto, Japan) for 15 minutes at 5°C. The RBC suspension 
was subsequently washed four times using PBS containing 
0.2% fetal bovine serum (FBS) (EIDIA Co. Ltd., Tokyo, Japan) 
and adjusted to a 0.25% cell suspension. Thereafter, 25 μL of 
this suspension was mixed with 50 μL monoclonal anti-A or 
anti-B (Bioclone Anti-A and Bioclone Anti-B, Ortho-Clinical 
Diagnostics, Tokyo, Japan) for 30 minutes at 5°C.11,12 After 
washing twice with PBS containing 0.2% FBS (PBS/FBS), a 
tagged antibody (goat anti-mouse IgG-FITC, BD Biosciences, 
San Jose, CA, USA) was added for 30 minutes at 5°C. After a 
final wash with PBS, the cells’ florescence was measured by 
FCM (FACSCalibur, BD Biosciences).
Setting the Gate for FCM
Using control RBCs (O and A1 or B groups), 
the G1 gate was set so that group O RBCs were 
99 percent negative for A or B antigens, and the 
G3 gate was set so that group A1 or B RBCs were 
99 percent positive for A or B antigens. When 
these gates were applied, only 0.1–0.3 percent 
of group O control RBCs showed nonspecific 
binding to anti-A or anti-B and only 0.1–0.4 
percent of group A1 or B RBCs were false 
negative. The G2 gate was set as the region 
between G1 and G3 (Fig. 2). The proportion 
of cell population detected in the G2 gate was 
calculated as follows: [G2 / (G1 + G2 + G3) × 
100].
Calculation of the Heterogeneity of 
Chimera Samples from a Standard 
Calibration Curve
The following artificial mixtures of A1 or B 
and O RBCs were prepared [(A1 or B) / (A1 or B 
+ O) × 100] and analyzed using FCM: 0, 10, 20, 
30, 40, 50, 60, 70, 80, 90, and 100 percent. A 
standard calibration curve of (G2 + G3) / (G1 + 
G2 + G3) was generated and used to estimate the 
ratios of cells in the chimera samples.
Results
The percentages of 23 ABO mosaics 
and 6 ABO chimeras detected in the G2 gate 
are presented in Tables 3 and 4. The mean 
percentages of mosaics and chimeras in the G2 
gate were 13.1 percent (range: 7.0–19.0%) and 
0.2 percent (range: 0.1–0.6%), respectively. 
Table 2. Summarized results of nucleotide substitutions in ABO exons 6 and 7 
Sample*
Position





















A mosaic 1 NT
A mosaic 2 — — T — — — — — — A102
A mosaic 3 NT
A mosaic 4 — — T — — — — — — A102
A mosaic 5 — — T — — — — — — A102
A mosaic 6 NT
A mosaic 7 — — T — — — — — — A102
A mosaic 8 — — T — — — — — — A102
A mosaic 9 — — T — — — — — — A102
A mosaic 10 NT
A mosaic 11 — — T — — — — — — A102
A mosaic 12 — — T — — — — — — A102
B mosaic 1 — G — G T A A C A B101
B mosaic 2 — G — G T A A C A B101
B mosaic 3 — G — G T A A C A B101
B mosaic 4 — G — G T A A C A B101
B mosaic 5 — G — G T A A C A B101
B mosaic 6 NT
B mosaic 7 NT
B mosaic 8 — G — G T A A C A B101
B mosaic 9 — G — G T A A C A B101
B mosaic 10 — G — G T A A C A B101







*GenBank accession no. AF134412. NT = not tested; ND = not determined.
IMMUNOHEMATOLOGY, Volume 31, Number 1, 2015 27
Distinguishing ABO mosaics from chimeras
Although the number of samples was small, the G2 values of 
mosaics were significantly higher than the values of chimeras 
(p < 0.001: Mann-Whitney U test). When the cutoff point 
was set to 1 percent to differentiate mosaics from chimeras, 
all analyzed cases were differentiated accurately and 
unambiguously.
We then attempted to estimate the proportion of the 
two different types of RBCs in the chimera samples using a 
standard linear curve that defines the relationship between 
the mixing ratio of artificial chimera samples and their values 
in the G3 gate. We obtained a linear curve, with the known 
concentrations on the y-axis and the measured variable on 
the x-axis (data not shown). The estimated ratios were almost 
consistent with the G1 and G3 gate values (Table 4).
Discussion
In the present study, we successfully established a clear and 
simple criterion for FCM analysis to differentiate ABO mosaics 
from ABO chimeras by setting the FCM histogram gates (G1 
and G3) for group “A” and/or “B” antigen-negative and -positive 
RBCs. We set these gates such that 99 percent negative RBCs 
and 99 percent positive RBCs were included in gates G1 and 
G3, respectively. The value of 99 percent set the cutoff point to 
1 percent to differentiate mosaics from chimeras. This value 
allowed us to unambiguously differentiate both types of RBCs. 
Furthermore, we attempted to determine heterogeneity based 
on data from artificial chimera samples with a known number 
of RBCs of each blood group.
After having established the proposed criteria, we 
performed serologic ABO blood group testing on 777,617 
Fig. 2. Determination of gate. Dot plots of negative (A) and positive (B) control samples. Gating regions were determined as 99 percent 
negative (G1, dotted line) and 99 percent positive (G3, dotted line). The G2 (solid line) gate was defined as the region between G1 and 
G3 indicated in images C and D, which are example dot plots of an A mosaic and A1 + O chimera sample, respectively. FITC = fluorescein 
isothiocyanate.
Table 3. ABO mosaic samples
Sample
% of gate (anti-A)
G1 G2 G3
A mosaic 1 17.6 11.8 70.6
A mosaic 2 36.7 19 44.3
A mosaic 3 66.8 8.7 24.5
A mosaic 4 17.6 13.7 68.7
A mosaic 5 20.6 13.8 65.6
A mosaic 6 55.5 7 37.5
A mosaic 7 40.4 14.4 45.2
A mosaic 8 23.5 17.4 59.1
A mosaic 9 32.9 12.6 54.5
A mosaic 10 24.5 10.2 65.3
A mosaic 11 37.1 18.8 44.1
A mosaic 12 45 10.7 44.3
Mean 34.9 13.1 52
Sample
% of gate (anti-B)
G1 G2 G3
B mosaic 1 27.7 11.3 61
B mosaic 2 19.5 10.9 69.6
B mosaic 3 35.3 17.3 47.4
B mosaic 4 28.9 13.8 57.3
B mosaic 5 18.3 12 69.7
B mosaic 6 44.9 14.8 40.3
B mosaic 7 32.7 16.8 50.5
B mosaic 8 45.6 11.9 42.5
B mosaic 9 43.2 10.8 46
B mosaic 10 61.1 15.3 23.6
B mosaic 11 46.8 8.5 44.7
— — — —
Mean 36.7 13.1 50.2
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donors as a routine test from December 2013 to October 
2014. Among the samples from all donors, nine samples were 
suspected to be mosaic or chimera based on serologic analyses; 
subsequent CPC analyses revealed that seven of these samples 
were mosaics and the remaining two samples were chimeras. 
When a validation test was performed using these nine 
samples, our proposed FCM criterion clearly discriminated 
between these mosaics and chimeras.
Although FCM analysis is widely used to distinguish ABO 
mosaics from ABO chimeras and hence our qualitative FCM 
system may not have a powerful impact on the differentiation 
of ABO mosaics and chimeras, we hope that it contributes 
to the introduction of more quantitative tests in the field of 
serologic blood typing.
Our FCM system has a drawback. Because it is necessary 
to set the G3 gate wide enough for a substantial number of 
mosaic RBCs to be counted in the G3 population, chimera 
RBCs in G2 should exhibit relatively high expression of A or 
B antigens. Therefore, A2 chimeras (e.g., A2 + O), the RBCs of 
which express only a limited amount of A or B antigens, cannot 
be distinguished from “A” mosaics. Although A2 is a rare blood 
group in Asian populations and is not a major problem in Asia, 
the possibility of finding an A2 blood type should be carefully 
considered when analyzing RBCs from people of European or 
African descent, because A2 is found in 8–10 percent of these 
populations.13
A. Oda et al.







G1 G2 G3 Negative Positive
Chimera 1 B + AB A 82.9 0.1 17 76 24
Chimera 2 O + B B 70.9 0.1 29 70 30
Chimera 3 A + AB B 56.1 0.6 43.3 55 45
Chimera 4 A + AB B 95 0.1 4.9 95 5
Chimera 5 O + B B 91.7 0.1 8.2 88 12
Chimera 6 O + A A 29.9 0.1 70 30 70
Mean — — 71.1 0.2 28.7 69 31
Constituent = red blood cell ABO group.
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